期刊文献+

原发性高血压病患者醛固酮逃逸现象的临床观察 被引量:4

The aldosterone escape in essential hypertensive patients
在线阅读 下载PDF
导出
摘要 目的观察原发性高血压病患者使用血管紧张素转换酶抑制剂(ACEI)依那普利后并发的醛固酮逃逸现象。方法65例原发性高血压病患者使用依那普利治疗,分别于治疗前及治疗后1、3、6个月采血,检测血管紧张素Ⅱ和醛固酮浓度,根据治疗3个月时的醛固酮浓度,判断有无并发醛固酮逃逸。结果依那普利治疗后1个月,AngⅡ、Ald与治疗前相比均下降,但3个月时,AngⅡ有所升高,Ald明显增高。65例中有28例并发醛固酮逃逸,发生率约43%。结论原发性高血压病患者长期(3个月以上)使用ACEI后,部分患者会出现醛固酮逃逸现象。 Objective To investigate aldosterone escape during angiotensin-converting enzyme inhibitor (ACEI) therapy in essential hypertensive(EH) patients. Methods 65 EH patients were treated with ACEI -enalapril. Plasma angiotensin Ⅱ(AngⅡ) and aldosterone(Ald) concentrations were measured by commercial radioimmunoassay after 1,3,6 months treatment respectively. Aldosterone escape was estimated by the plasma Ald levels after 3 months treatment. Results After 1 month enalapril treatment, beth the plasma Ang Ⅱ and Aid concentrations of the patients decreased compared with before treatment. But after 3 months treatment, the plasma Ang Ⅱ levels increased slightly, the plasma Aid levels increased significantly. Aldosterone escape was observed in 28 of 65 patients after 3 months enalapril treatment,the incidence of aldosterone escape was 43%. Conclusion Aldosterone escape may occur during continuous(〉3 months) ACEI therapy in some of EH patients.
出处 《中国心血管病研究》 CAS 2006年第11期840-842,共3页 Chinese Journal of Cardiovascular Research
关键词 高血压 醛固酮 Hypertension Aldosterone
  • 相关文献

参考文献10

  • 1[1]Mantero F,Lucarelli G.Aldosterone antagonists in hypertension and heart failure.Ann-Endocrinol-(Pan/s),2000,61:52-60.
  • 2[2]Dahlstron D,Kaelsson E.Captopril and spirondatone therapy for refractory congestive heart failure.Am J Cardiol,1993,71:29A.
  • 3[3]Fritsch-Neves M,Schiffrin EL.Aldosterone:a risk factor for vascular disease.Curr Hypertens Rep,2003,5:59-65.
  • 4陈广华,石增成,张梅.醛固酮拮抗剂依普利酮治疗高血压病研究进展[J].中国心血管病研究,2004,2(12):987-990. 被引量:9
  • 5[5]Sato A,Saruta T.Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patiens with left ventricular hypertrophy.J Int Med Res,2001,29:13-21.
  • 6[6]Lee AF,Mac Fadyen RJ,Struthera AD.Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy; a longiyudinal study.Eur J Heart Fail,1999,1:401-406.
  • 7[7]The RALES Investigators.Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitorand a loop diuretic for severe congestive heart failure (the randomized aldactone evaluation study RALES).Am J Cardiol,1996,78:902-907.
  • 8[8]Dzau VJ,Hirsch A.Emerging role of tissue rennin-angiotensin systems in congestive heart failure.Eur heart J,1990,11:65-71.
  • 9[9]Urata H,Strobel F,Ganten D.Widespread tissue distribution of human chymase.J Hypertens,1994,12(Suppl):S17-S22.
  • 10[10]Cicoira M,Zanolla L,Rossi A,et al.Failure of aldosterone suppression despite angiotensin-converting enzyme inhibitor (ACEI) administration in chronic heart failure is associated with ACE DD genotype.J Am Coll Cardiol,2001,37:1808-1812.

二级参考文献15

  • 1[1]Satoh M, Nakamura M, Saitoh H. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart [J]. Clin Sci (Lond), 2002, 102:387 - 392
  • 2[3]Davis KL, Nappi JM. The cardiovascular effects of eplerenone, a selective aldosterone - receptor antagonist [J]. Clin Ther, 2003, 25(11):2647 - 2668
  • 3[4]Rocha R, Martin - Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotension Ⅱ/salt - induced vascular inflammation in the rat heart[J]. Endocrinplogy, 2002,143(12):4828 - 4836
  • 4[5]Rocha R, Stier CT, Kifor I, et al. Aldosterone:A mediator of myocardial necrosis and renal arteriopathy[J].Endocrinplogy, 2000, 141 (10):3871 - 3878
  • 5[6]Quaschning T, Ruschitzka F, Shaw S, et al. Aldosterone receptor antagonism normalizes vascular function in liquorice - induced hypertension [J]. Hypertension,2001,37:801 - 816
  • 6[7]De Paula RB, Da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity- induced hypertension and glomerular hyperfiltration [J]. Hypertension, 2004, 43(1):41 - 47
  • 7[8]Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild - tomoderate hypertension[J]. Am J Hypertens, 2002, 15(8):709 - 716
  • 8[9]White WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension[J]. Am J Cardiol, 2003, 92 (1):38 - 42
  • 9[10]Burgess ED, Lacourciere Y, Ruilope - Urioste LM, et al. Long- term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension[J]. Clin Ther, 2003, 25 (9):2388 -2404
  • 10[11]Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to rennin- angiotension blockade in hypertensive patients[J]. Hypertension, 2002, 40 (2):117 - 123

共引文献8

同被引文献17

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部